סך נכסי הפעילות העסקית Addex Therapeutics Ltd. (ADXN)

Addex Therapeutics (ADXN) is managed by Swiss experts with a strong scientific background, ensuring process transparency and effective capital control. The financial model relies on the development of small molecules for the therapy of nervous system disorders, while current funding is provided by grants and partnership payments. Total assets amount to 7.50. The daily price action underscores the business's independence from market volatility, shifting focus toward the success of clinical trials.

Addex Therapeutics (ADXN) leverages a strategy of outsourcing production and clinical trials to minimize capital expenditures, which is reflected in the calculation logic of total assets derived reverse-engineered through ROA. This indicator aggregates equity and liabilities, allowing investors to assess the actual scale of business resources, while the current level of balance sheet assets demonstrates capital management efficiency without the need for owning proprietary manufacturing plants.